IRVINE, Calif.--(EON: Enhanced Online News)--Khang & Khang LLP (the “Firm”) announces the filing of a class action
lawsuit against Egalet Corporation (“Egalet” or the “Company”) (Nasdaq:
EGLT). Investors who purchased or otherwise acquired Egalet shares
between December 15, 2015, and January 9, 2017, inclusive (the “Class
Period”), are encouraged to contact the firm in advance of the March 28,
2017 lead plaintiff deadline.

“no
other single-entity extended-release morphine product submitted in an
abbreviated new drug application or 505(b)(2) application can be
approved for that use at this time.”

On January 9, 2017, Egalet released a statement concerning approval for
its product Arymo ER. The same day, the U.S. Federal Drug Administration
stated that a competitor product MorphaBond “has marketing exclusivity
for labeling describing the expected reduction of abuse of single-entity
extended-release morphine by the intranasal route due to physicochemical
properties.” Because of MorphaBond’s exclusivity within this market, “no
other single-entity extended-release morphine product submitted in an
abbreviated new drug application or 505(b)(2) application can be
approved for that use at this time.” When this information was revealed
to the investing public, the value of Egalet stock fell, causing
investors harm.

There has been no class certification in this case. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.

If you wish to learn more about this lawsuit at no charge, or if you
have questions concerning this notice or your rights, please contact
Joon M. Khang, a prominent litigator for almost two decades, by
telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some
jurisdictions.

Recent Stories

IRVINE, Calif.--(EON: Enhanced Online News)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against General Motors Company (“GM” or the “Company”) (NYSE: GM) concernin... more »